Business · 04/02/2022
FDA Releases Draft Guidance on Immunogenicity Information in Prescription Drug Labeling
The FDA is releasing a draft guidance to help pharmaceutical companies include clinically relevant immunogenicity information in the labeling of prescription drugs and biological products, aiming to promote safe and effective use.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →